Marpai (MRAI)
OTHER OTC:MRAI
MRAI Stock Chart & Stats
$0.73
-$0.08(-7.69%)
At close: 4:00 PM EST
$0.73
-$0.08(-7.69%)
Day’s Range― - ―
52-Week Range$0.23 - $1.78
Previous CloseN/A
Volume51.03K
Average Volume (3M)20.43K
Market Cap
$8.35M
Enterprise Value$6.39M
Total Cash (Recent Filing)$133.00K
Total Debt (Recent Filing)$792.00K
Price to Earnings (P/E)―
Beta-0.27
Next Earnings
May 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.26
Shares Outstanding25,292,667
10 Day Avg. Volume21,648
30 Day Avg. Volume20,435
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.34
Price to Sales (P/S)0.61
P/FCF Ratio-1.47
Enterprise Value/Market Cap0.77
Enterprise Value/Revenue0.35
Enterprise Value/Gross Profit1.35
Enterprise Value/Ebitda-0.49
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Operational ConsolidationCentralizing claims processing into one advanced operating system reduces recurring complexity and manual handling, lowering operating costs and error rates. Over months this improves scalability and gross-margin potential, enabling the TPA to service more clients from the same cost base and support a path to profitability.
Product Differentiation (MarpaiRx)MarpaiRx represents a proprietary pharmacy-management capability that helps win and retain employer plan clients. Durable product differentiation increases client stickiness and per-client revenue potential, improving long-term margin sustainability and competitive positioning in the crowded TPA market.
Fresh Capital To Execute PlanThe $3.9M PIPE provides near-term runway to complete the turnaround initiatives (tech consolidation, sales expansion). This financing supports execution of structural cost and growth projects that materially affect results over several quarters, increasing the likelihood of achieving durable operational improvements.
Bears Say
Steep Revenue DeclineA sharp loss of scale materially weakens unit economics for a TPA business that benefits from volume. Shrinking top line undermines fixed-cost absorption, reduces pricing leverage with vendors, constrains reinvestment in sales and product, and makes margin recovery and sustained growth far harder without a durable rebound in new business.
Negative EquityAccumulated losses producing deep negative equity signal a weak capital base and limited capacity to absorb shocks. This restricts access to traditional financing, raises dilution or restructuring risk, and forces management to prioritize liquidity over strategic investments, complicating any long-term recovery plan.
Weak Cash Generation & Insider BridgeOperating and free cash flow remain negative (~ -$7.5M in 2025) with limited unrestricted cash; reliance on short‑dated CEO promissory notes evidences fragile liquidity. Dependence on related‑party financing increases governance and execution risk and constrains the company’s ability to invest for growth or withstand setbacks.
Marpai News
MRAI FAQ
What was Marpai’s price range in the past 12 months?
Marpai lowest stock price was $0.23 and its highest was $1.78 in the past 12 months.
What is Marpai’s market cap?
Marpai’s market cap is $8.35M.
When is Marpai’s upcoming earnings report date?
Marpai’s upcoming earnings report date is May 13, 2026 which is in 38 days.
How were Marpai’s earnings last quarter?
Marpai released its earnings results on Apr 01, 2026. The company reported -$0.264 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.264.
Is Marpai overvalued?
According to Wall Street analysts Marpai’s price is currently Overvalued.
Does Marpai pay dividends?
Marpai does not currently pay dividends.
What is Marpai’s EPS estimate?
Marpai’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Marpai have?
Marpai has 25,292,667 shares outstanding.
What happened to Marpai’s price movement after its last earnings report?
Marpai reported an EPS of -$0.264 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.103%.
Which hedge fund is a major shareholder of Marpai?
Currently, no hedge funds are holding shares in MRAI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Marpai
Marpai, Inc., a technology-driven healthcare payer, focuses on providing services to the self-insured employer market in the United States and Israel. The company offers ancillary services, such as care management, case management, actuarial services, health savings account administration, and cost containment services. It also develops artificial intelligence and healthcare technology that enables the analysis of data to predict and prevent events related to diagnostic errors, hospital visits, and administrative issues. The company was incorporated in 2021 and is headquartered in New York, New York.
MRAI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant operational improvements and strategic initiatives like cost reduction and new client acquisitions. However, the notable decline in net revenues and ongoing operating losses temper these achievements.View all MRAI earnings summariesTechnical Analysis
Ownership Overview
66.67% Insiders
0.09% Other Institutional Investors
33.24% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---